Poster

Real-World Treatment Experiences and Expectations by Symptom Severity in Patients With Major Depressive Disorder

Abstract: Major Depressive Disorder (MDD) is characterized by depressed mood, anhedonia, and diminished quality of life. The varying severity of MDD symptoms impacts treatment response an...

08/20/2024

Risk of Relapse among Medicare Advantage Members Diagnosed with Schizophrenia and Receiving Once-monthly Paliperidone Palmitate or First Generation Long-acting Injectable Antipsychotics

Abstract: Assessment of real-world outcomes associated with different antipsychotics helps inform treatment selection for patients with schizophrenia. This real-world study aimed to compa...

08/20/2024

Safety and Exposure of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA) Formulation of Risperidone, in Adolescent and Young Adult Patients With Schizophrenia: Results From the Phase 3 RISE and SHINE Studies

Abstract: Background: Two phase 3 trials evaluating TV-46000 for schizophrenia enrolled patients aged 13–65 years. Adolescents aged 13–18 years and young adults aged 19–21 years who recei...

08/20/2024

Psychiatric Nurse Perceptions of Long-Acting Injectable Therapies for Treating Schizophrenia: Qualitative Results From the Multinational ADVANCE Study

Abstract: Background: Psychiatric nurses play a key role in schizophrenia treatment; their perceptions of long-acting injectable antipsychotics (LAIs) vary. The objectives of the Attitude...

08/20/2024

Putting it All Together in Bipolar Disorder: Novel Treatment Options Focused on the Whole Patient

Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertre...

08/20/2024

Real-World AXS-05 Patient Characteristics in Major Depressive Disorder

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion), a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, gained approval from the US FDA i...

08/20/2024

Real-world Change in Depressive Symptoms Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray

Abstract: BACKGROUND: Real-world evidence of clinical benefits of esketamine nasal spray for treatment-resistant depression (TRD) is limited. This study used health insurance claims data ...

08/20/2024

Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings

Abstract: Tardive dyskinesia (TD) is a persistent and potentially debilitating movement disorder associated with antipsychotic exposure. Older adults have an increased risk for TD and may...

08/20/2024

Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 58 Months After Approval in the United States

Abstract: Purpose: To examine real-world incidence of esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., actively solicited events of sedation, diss...

08/20/2024

Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study

Abstract: Background: Long-term safety, tolerability, and durability of therapeutic effect are important aspects of antipsychotic treatment. Methods: This phase 3, multicenter, open-lab...

08/20/2024